Opko Health (OPK)

As of 30 September 2026, short interest in OPK is 35,560,259 shares, up 1,001,887 shares over the last month. Over the last 48 readings it ranged from 30,340,574 shares (31 December 2025) to 116,494,002 shares (31 March 2025). The latest reading sits at the bottom of that range. At the reported average volume of 2.4M shares a day that is 14.9 days to cover.

<iframe src="https://xoomar.com/embed/stocks/opk" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of OPK volume is 28.0%, down 30.6 points over the last five sessions. Over the last 30 readings it ranged from 28.0% (9 October 2026) to 59.7% (10 September 2026). The latest reading sits at the bottom of that range. The latest reading is 18.1 points below the 30-session average of 46.1%, on 413K shares reported.

As of 14 September 2026, the fails-to-deliver balance in OPK is 3,327 shares, up 2,482 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (26 August 2026) to 100,573 shares (7 August 2026). The latest reading sits at the bottom of that range.

No open-market insider trades were reported for OPK in the last 90 days. The most recent filings are listed below. Latest filing: Rubin Steven D (Executive VP-Administration) on 2026-07-24.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

2 holders report 5% or more of OPK in their latest filing, all on Schedule 13D (active intent). The largest reported stake is FROST PHILLIP MD ET AL at 34.1% of the class (255,429,406 shares), filed 2026-07-01 for an event on 2026-06-29.

5 of the 30 tracked managers held OPK at their latest 13F, $4.6M in total at quarter-end prices. Citadel Advisors is the largest at $2.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) Opko Health reported revenue of $163.6M, up 4.3% from the same quarter a year earlier, and net loss of $8.4M (-0.01 diluted EPS). In FY 2025 it generated -$178.5M of operating cash flow and spent $47.0M on buybacks. As of 2026-06-30, cash was $300.8M against $349.1M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-17 from the cover page.